Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma

M. Santoni, U. De Giorgi, R. Iacovelli, A. Conti, L. Burattini, L. Rossi, S. Luca Burgio, R. Berardi, G. Muzzonigro, E. Cortesi, D. Amadori, S. Cascinu

Research output: Contribution to journalArticle

Abstract

Background:Everolimus is a mammalian target of rapamycin inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between pre-treatment neutrophil-to-lymphocyte ratio (NLR) and the outcome of patients treated with everolimus for mRCC.Methods:Ninety-seven patients with mRCC were treated with everolimus till April 2013 in our institutions. Patients were stratified in two groups with NLR >3 (Group A) vs

Original languageEnglish
Pages (from-to)1755-1759
Number of pages5
JournalBritish Journal of Cancer
Volume109
Issue number7
DOIs
Publication statusPublished - Oct 1 2013

Fingerprint

Renal Cell Carcinoma
Neutrophils
Lymphocytes
Sirolimus
Therapeutics
Everolimus

Keywords

  • everolimus
  • mTOR inhibitors
  • neutrophil-tolymphocyte ratio
  • renal cell carcinoma
  • targeted therapy
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma. / Santoni, M.; De Giorgi, U.; Iacovelli, R.; Conti, A.; Burattini, L.; Rossi, L.; Luca Burgio, S.; Berardi, R.; Muzzonigro, G.; Cortesi, E.; Amadori, D.; Cascinu, S.

In: British Journal of Cancer, Vol. 109, No. 7, 01.10.2013, p. 1755-1759.

Research output: Contribution to journalArticle

Santoni, M. ; De Giorgi, U. ; Iacovelli, R. ; Conti, A. ; Burattini, L. ; Rossi, L. ; Luca Burgio, S. ; Berardi, R. ; Muzzonigro, G. ; Cortesi, E. ; Amadori, D. ; Cascinu, S. / Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma. In: British Journal of Cancer. 2013 ; Vol. 109, No. 7. pp. 1755-1759.
@article{c4cbffe3e3454fa78774ae0602661734,
title = "Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma",
abstract = "Background:Everolimus is a mammalian target of rapamycin inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between pre-treatment neutrophil-to-lymphocyte ratio (NLR) and the outcome of patients treated with everolimus for mRCC.Methods:Ninety-seven patients with mRCC were treated with everolimus till April 2013 in our institutions. Patients were stratified in two groups with NLR >3 (Group A) vs",
keywords = "everolimus, mTOR inhibitors, neutrophil-tolymphocyte ratio, renal cell carcinoma, targeted therapy, tyrosine kinase inhibitor",
author = "M. Santoni and {De Giorgi}, U. and R. Iacovelli and A. Conti and L. Burattini and L. Rossi and {Luca Burgio}, S. and R. Berardi and G. Muzzonigro and E. Cortesi and D. Amadori and S. Cascinu",
year = "2013",
month = "10",
day = "1",
doi = "10.1038/bjc.2013.522",
language = "English",
volume = "109",
pages = "1755--1759",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma

AU - Santoni, M.

AU - De Giorgi, U.

AU - Iacovelli, R.

AU - Conti, A.

AU - Burattini, L.

AU - Rossi, L.

AU - Luca Burgio, S.

AU - Berardi, R.

AU - Muzzonigro, G.

AU - Cortesi, E.

AU - Amadori, D.

AU - Cascinu, S.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Background:Everolimus is a mammalian target of rapamycin inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between pre-treatment neutrophil-to-lymphocyte ratio (NLR) and the outcome of patients treated with everolimus for mRCC.Methods:Ninety-seven patients with mRCC were treated with everolimus till April 2013 in our institutions. Patients were stratified in two groups with NLR >3 (Group A) vs

AB - Background:Everolimus is a mammalian target of rapamycin inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between pre-treatment neutrophil-to-lymphocyte ratio (NLR) and the outcome of patients treated with everolimus for mRCC.Methods:Ninety-seven patients with mRCC were treated with everolimus till April 2013 in our institutions. Patients were stratified in two groups with NLR >3 (Group A) vs

KW - everolimus

KW - mTOR inhibitors

KW - neutrophil-tolymphocyte ratio

KW - renal cell carcinoma

KW - targeted therapy

KW - tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84885182189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885182189&partnerID=8YFLogxK

U2 - 10.1038/bjc.2013.522

DO - 10.1038/bjc.2013.522

M3 - Article

C2 - 24008663

AN - SCOPUS:84885182189

VL - 109

SP - 1755

EP - 1759

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 7

ER -